Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease control · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
Mortality (at 6 months) · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · bullous pemphigoid
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
1 finding from 1 review
In the Hegarty 2002 cross-over trial (n=22), no statistical testing of the pain score (VAS 0 to 100) was reported; it is not clear whether the difference is statistically significant (fluticasone mean score 19.8 versus…
1 study · 22 participants
GRADE not reported
Reduction in target/mean lesion size · People with erosive oral lichen planus
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Hegarty 2002: nausea (4), swollen mouth (1), bad taste and smell (6), difficulty in spray application (7), dry mouth (2), sore throat (1), red painful tongue (1), and pseudomembranous…
1 study · 44 participants
GRADE not reported
Disease control (time when steroid could be discontinued) · bullous pemphigoid
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported
Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus
Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review